
Psyence Group (OTCQB:PSYGF) and Filament Health Corp. (OTCQB:FLHLF) announced the signing of a licensing agreement: Filament is to license its proprietary psilocybin derived drug, PEX010, and the associated IP to Psyence for use in its upcoming clinical trials.
Thanks to this license, Psyence will have exclusivity for the drug in the United Kingdom for studying its effects on anxiety and depression and associated ailments within the context of palliative care.